Immediate Impact

50 standout
Sub-graph 1 of 25

Citing Papers

The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
2 intermediate papers

Works of Adel Nada being referenced

Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.
2014
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: Design of the RENEW study
2013

Author Peers

Author Last Decade Papers Cites
Adel Nada 42 83 123 133 84 30 456
Yijie Hu 13 28 82 150 102 35 509
Feng Ran 17 28 184 113 24 32 467
Michael Neumeier 73 27 43 96 98 12 494
Justin Lowenthal 51 30 58 169 155 15 452
Marcel Costuleanu 12 8 53 127 26 40 416
Kimihiro Suzuki 71 57 29 106 49 51 491
Albert Rabinovitch 12 16 179 112 15 18 500
E Constantinescu 14 11 59 142 32 37 493
Naoki Makita 49 33 38 209 28 39 491
Chao Tang 7 12 54 169 31 33 494

All Works

Loading papers...

Rankless by CCL
2026